See more : Ascentech K.K. (3565.T) Income Statement Analysis – Financial Results
Complete financial analysis of Navidea Biopharmaceuticals, Inc. (NAVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Navidea Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Facephi Biometria, S.A. (ALPHI.PA) Income Statement Analysis – Financial Results
- Range Resources Corporation (RRC) Income Statement Analysis – Financial Results
- VAT Group AG (VACN.SW) Income Statement Analysis – Financial Results
- Mastech Digital, Inc. (MHH) Income Statement Analysis – Financial Results
- Aspen Pharmacare Holdings Limited (APN.JO) Income Statement Analysis – Financial Results
Navidea Biopharmaceuticals, Inc. (NAVB)
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.65K | 531.51K | 915.01K | 26.62K | 322.52K | 1.81M | 21.97M | 13.25M | 6.27M | 1.13M | 78.74K | 597.73K | 10.70M | 9.52M | 7.89M | 7.12M | 6.05M | 5.92M | 5.95M | 6.51M | 4.92M | 7.58M | 9.71M | 9.45M | 5.83M | 5.13M | 1.17M | 1.00M | 900.00K | 100.00K | 100.00K |
| Cost of Revenue | 184.95K | 198.83K | 1.05K | 6.67K | 96.64K | 3.65K | 2.30M | 1.75M | 1.59M | 332.82K | 0.00 | 0.00 | 3.21M | 3.13M | 3.01M | 3.18M | 2.63M | 2.38M | 2.34M | 3.12M | 2.35M | 4.39M | 4.63M | 3.95M | 1.40M | 1.58M | 676.77K | 500.00K | 100.00K | 5.90M | 100.00K |
| Gross Profit | -119.30K | 332.68K | 913.97K | 19.95K | 225.89K | 1.81M | 19.67M | 11.49M | 4.69M | 797.82K | 78.74K | 597.73K | 7.49M | 6.38M | 4.88M | 3.94M | 3.42M | 3.54M | 3.61M | 3.38M | 2.57M | 3.20M | 5.08M | 5.49M | 4.43M | 3.55M | 494.41K | 500.00K | 800.00K | -5.80M | 0.00 |
| Gross Profit Ratio | -181.71% | 62.59% | 99.89% | 74.95% | 70.04% | 99.80% | 89.54% | 86.76% | 74.72% | 70.56% | 100.00% | 100.00% | 70.03% | 67.07% | 61.83% | 55.30% | 56.50% | 59.86% | 60.61% | 52.00% | 52.22% | 42.17% | 52.31% | 58.13% | 75.93% | 69.27% | 42.21% | 50.00% | 88.89% | -5,800.00% | 0.00% |
| Research & Development | 5.97M | 5.14M | 4.93M | 5.34M | 4.22M | 4.51M | 8.88M | 12.79M | 16.78M | 23.71M | 16.89M | 15.15M | 9.22M | 4.97M | 4.51M | 2.87M | 3.80M | 4.03M | 2.45M | 1.89M | 2.32M | 344.68K | 472.73K | 1.31M | 12.96M | 19.66M | 16.08M | 7.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 7.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.96M | 7.45M | 6.69M | 6.28M | 7.70M | 11.17M | 13.01M | 17.26M | 15.54M | 15.53M | 11.18M | 9.55M | 4.58M | 3.24M | 3.41M | 2.84M | 3.08M | 3.16M | 3.15M | 3.10M | 3.27M | 2.32M | 2.96M | 8.21M | 10.55M | 11.16M | 7.75M | 3.60M | 12.00M | 2.30M | 2.90M |
| Other Expenses | 0.00 | -14.12K | -21.86K | -631.21K | 1.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 552.96K | 9.38M | 0.00 | 0.00 | 500.00K | 600.00K | 100.00K | 100.00K |
| Operating Expenses | 13.93M | 12.59M | 11.63M | 10.98M | 11.07M | 15.68M | 21.90M | 30.05M | 32.32M | 39.24M | 28.07M | 24.70M | 13.80M | 8.21M | 7.92M | 41.23M | 6.88M | 7.19M | 5.61M | 5.00M | 5.59M | 2.67M | 3.43M | 10.07M | 32.90M | 30.82M | 23.84M | 11.90M | 12.60M | 2.40M | 3.00M |
| Cost & Expenses | 14.12M | 12.59M | 11.63M | 10.99M | 11.17M | 15.69M | 24.19M | 31.80M | 33.91M | 39.57M | 28.07M | 24.70M | 17.01M | 11.34M | 10.93M | 44.42M | 9.51M | 9.56M | 7.95M | 8.12M | 7.94M | 7.05M | 8.06M | 14.03M | 34.30M | 32.39M | 24.51M | 12.40M | 12.70M | 8.30M | 3.10M |
| Interest Income | 0.00 | 6.00K | 11.34K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 16.10K | 18.84K | 25.04K | 25.76K | 8.80K | 18.75K | 60.86K | 70.98K | 225.47K | 226.66K | 28.87K | 9.42K | 74.26K | 127.66K | 205.96K | 0.00 | 598.83K | 0.00 | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.10M | 6.36K | 0.00 | 25.29K | 30.80K | 168.97K | 4.87K | 1.27M | 3.71M | 2.78M | 1.17M | 13.33K | 554.99K | 1.53M | 1.74M | 2.28M | 1.50M | 1.35M | 334.20K | 186.91K | 31.95K | 11.10K | 24.88K | 0.00 | 189.79K | 0.00 | 83.44K | 200.00K | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 95.82K | 198.83K | 190.58K | 144.51K | 150.39K | 254.59K | 501.37K | 571.42K | 500.18K | 404.18K | 200.22K | 176.54K | 223.46K | 333.75K | 408.35K | 1.81M | 1.22M | 1.29M | 856.01K | 757.78K | 796.83K | 423.12K | 392.50K | 552.96K | 1.12M | 896.52K | 652.62K | -500.00K | -600.00K | -100.00K | -100.00K |
| EBITDA | -13.88M | -11.51M | -10.64M | -10.82M | -10.85M | -13.14M | -6.87M | -21.31M | -31.52M | -38.03M | -27.79M | -24.86M | -49.10M | -35.85M | -2.48M | -2.40M | -2.83M | -2.97M | -1.14M | -853.34K | -2.22M | 955.59K | 1.67M | -4.03M | -27.20M | -26.37M | -22.97M | -11.80M | -12.10M | -8.40M | -3.10M |
| EBITDA Ratio | -21,134.32% | -2,337.93% | -1,170.60% | -41,184.60% | -1,722.58% | -541.05% | -20.54% | -114.85% | -448.72% | -3,399.73% | -35,547.39% | -3,998.82% | 345.15% | 341.96% | -27.82% | -482.39% | -36.85% | -37.03% | 1.57% | -12.95% | -45.50% | 20.93% | 17.16% | -46.74% | -469.25% | -551.70% | -1,960.93% | -1,180.00% | -1,344.44% | -8,400.00% | -3,100.00% |
| Operating Income | -14.05M | -12.06M | -10.71M | -10.96M | -10.85M | -13.88M | -2.22M | -18.55M | -27.63M | -38.44M | -27.99M | -24.10M | -6.31M | -1.82M | -3.04M | -1.76M | -3.46M | -3.64M | -2.00M | -1.61M | -2.99M | -352.21K | 1.29M | -4.58M | -28.47M | -27.26M | -23.34M | -11.40M | -11.80M | -8.20M | -3.00M |
| Operating Income Ratio | -21,402.08% | -2,269.07% | -1,170.60% | -41,184.60% | -3,363.29% | -766.50% | -10.12% | -140.01% | -440.38% | -3,399.73% | -35,547.39% | -4,032.67% | -58.98% | -19.17% | -38.57% | -24.74% | -57.19% | -61.56% | -33.58% | -24.75% | -60.82% | -4.64% | 13.25% | -48.50% | -488.08% | -531.69% | -1,993.02% | -1,140.00% | -1,311.11% | -8,200.00% | -3,000.00% |
| Total Other Income/Expenses | -1.13M | 345.52K | -10.51K | 17.68K | -5.32M | -3.91M | 2.77M | -10.32M | -13.14M | -4.26M | -1.17M | -943.16K | -37.20M | 1.82M | -2.12M | -3.33M | -1.28M | -1.28M | -1.24M | -10.38K | 28.48K | 369.77K | 371.83K | 386.58K | 26.50K | 1.92M | 276.87K | 900.00K | 900.00K | 300.00K | 200.00K |
| Income Before Tax | -15.18M | -11.71M | -10.72M | -10.94M | -16.17M | -17.79M | -14.31M | -28.76M | -35.73M | -42.70M | -29.16M | -25.05M | -49.96B | -39.61B | -5.17B | -5.09B | -4.74B | -4.93B | -3.24M | -1.62M | -2.96M | 17.57K | 1.66M | -4.19M | -28.44M | -25.34M | -23.07M | -10.50M | -10.90M | -7.90M | -2.80M |
| Income Before Tax Ratio | -23,117.58% | -2,204.06% | -1,171.75% | -41,118.20% | -5,013.18% | -982.62% | -65.13% | -217.05% | -569.36% | -3,776.61% | -37,030.66% | -4,190.46% | -466,936.68% | -416,112.49% | -65,509.12% | -71,415.40% | -78,353.34% | -83,266.70% | -54.36% | -24.91% | -60.24% | 0.23% | 17.08% | -44.41% | -487.63% | -494.19% | -1,969.38% | -1,050.00% | -1,211.11% | -7,900.00% | -2,800.00% |
| Income Tax Expense | 0.00 | 16.04K | -81.74K | 707.00 | 2.75K | -4.06M | -648.00K | -436.05K | 2.68M | 2.37M | 43.33M | -7.88M | 43.65M | 37.45M | 2.12M | -32.20M | 1.28M | 1.28M | 1.54M | 187.87K | -726.00 | 2.62K | -194.07K | -407.40K | -435.54K | -4.02M | -2.37M | 400.00K | 200.00K | 0.00 | -200.00K |
| Net Income | -15.18M | -11.73M | -10.64M | -10.95M | -16.13M | 74.95M | -14.31M | -27.56M | -35.73M | -42.70M | -29.16M | 5.61M | -49.96M | -39.61M | -5.17M | -5.09M | -4.74M | -4.93M | -3.54M | -1.80M | -2.96M | 14.95K | 1.84M | -4.17M | -28.03M | -23.25M | -20.97M | -10.80M | -10.80M | -8.00M | -2.60M |
| Net Income Ratio | -23,117.58% | -2,207.08% | -1,162.82% | -41,120.85% | -5,000.12% | 4,139.67% | -65.13% | -208.03% | -569.36% | -3,776.61% | -37,030.66% | 939.05% | -466.94% | -416.11% | -65.51% | -71.42% | -78.35% | -83.27% | -59.49% | -27.63% | -60.23% | 0.20% | 18.95% | -44.19% | -480.61% | -453.33% | -1,790.42% | -1,080.00% | -1,200.00% | -8,000.00% | -2,600.00% |
| EPS | -0.59 | -0.40 | -0.45 | -0.76 | -1.89 | 9.40 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.45 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| EPS Diluted | -0.56 | -0.40 | -0.45 | -0.76 | -1.89 | 9.00 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.31 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| Weighted Avg Shares Out | 29.34M | 29.34M | 23.90M | 14.39M | 8.53M | 8.08M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.29M | 1.29M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
| Weighted Avg Shares Out (Dil) | 30.90M | 29.34M | 23.90M | 14.39M | 8.53M | 8.30M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.30M | 1.32M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company's Phase 3 Trial in Rheumatoid Arthritis
DUBLIN, Ohio--( BUSINESS WIRE )--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced enrollment of the 50th participant in the Company's pivotal NAV3-33 Phase 3...
Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q3 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Michael Rosol – Chief Medical Officer Erika Eves – Vice President-Finance and Administration Conference Call Participants Michael Okunewitch – Maxim Group Mike...
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
DUBLIN, Ohio--(BUSINESS WIRE)--The seventh bullet under Third Quarter 2022 Highlights and Subsequent Events should read: Received an additional $1.0 million under a bridge loan from the Company’s Vice Chair of the Board of Directors, John K. Scott, Jr. (Instead of:...
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
DUBLIN, Ohio--( BUSINESS WIRE )--The seventh bullet under Third Quarter 2022 Highlights and Subsequent Events should read: Received an additional $1.0 million under a bridge loan from the Company's Vice Chair of the Board of Directors, John K. Scott, Jr. (Instead...
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
DUBLIN, Ohio--( BUSINESS WIRE )--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and nine-month periods ended September 30,...
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced details of the results from the Company's ongoing preclinical studies evaluating targeted immunotherapy for...
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, November 15, 2022 at...
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that results from the Company's ongoing preclinical studies evaluating targeted immunotherapy for cancer based...
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Joshua (“Josh”) Wilson to its Board of Directors, effective September 30,...
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the results from the Company's completed NAV3-31 Phase 2B clinical study as well...
Source: https://incomestatements.info
Category: Stock Reports